Aristides Capital’s Hepion Pharmaceuticals HEPA Stock Holding History

Aristides Capital’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-49	Closed	-$56K	–	231
2021 Q4	$56K	Buy	+49	New	+$67.1K	0.03%	258

Other funds holding HEPA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

McAdam LLC Philadelphia, Pennsylvania $2.22B AUM 16.98% 1-Year Est. Return

Aristides Capital's HEPA Position: Q1 2022 in Review

Aristides Capital sold out of Hepion Pharmaceuticals (HEPA) in Q1 2022, closing a stake of 49 shares — an estimated $56K sold.

Aristides Capital first reported a position in HEPA in Q4 2021 and held it in 1 quarter. The position peaked at $56K in Q4 2021. 31 funds tracked by Wall St. Rank hold HEPA as of Q1 2022.

Aristides Capital reported no remaining Hepion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Aristides Capital sold 49 Hepion Pharmaceuticals shares in Q1 2022, an estimated $56K.
Aristides Capital first reported a position in Hepion Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Aristides Capital's Hepion Pharmaceuticals position peaked at $56K in Q4 2021.
31 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.